Michael Jensen
Michael Jensen is the Founder and Chief Scientific Officer at BrainChild Bio, a startup where he continues to lead scientific efforts.
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR T trial for childhood DIPG
Seattle startup BrainChild Bio raised $116 million in Series A funding to advance a CAR T cell therapy for diffuse intrinsic pontine glioma (DIPG) and to support development of additional pediatric and adult brain tumor CAR T programs. The financing will fund a pivotal ILLUMINATE Phase 2 registration-stage trial and was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.
BrainChild Bio raises $116M Series A to fund pivotal B7-H3 CAR-T trial for pediatric DIPG
BrainChild Bio raised $116 million in a Series A to fund a pivotal trial of a B7-H3–targeted CAR-T therapy for pediatric diffuse intrinsic pontine glioma (DIPG), aiming to make CAR-Ts function more like small molecules for brain tumors.
BrainChild Bio raises $116M Series A to launch pivotal registrational trial of BCB-276 CAR T therapy for pediatric DIPG
BrainChild Bio, a Seattle Children’s spinout, raised $116 million in Series A funding to support a pivotal registrational trial of BCB-276, an autologous CAR T-cell therapy targeting DIPG in children, with plans to expand into adult CNS tumors including glioblastoma.
BrainChild Bio raises $116M Series A from Seattle Children’s and WRF to fund pivotal CAR-T trial for DIPG
BrainChild Bio, spun out of Seattle Children’s Hospital, raised $116 million in a Series A led by Seattle Children’s and WRF Capital to fund a pivotal phase 2 trial of CAR-T candidate BCB-276 for diffuse intrinsic pontine glioma (DIPG) and advance a planned phase 1 glioblastoma program.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR‑T trial for pediatric diffuse intrinsic pontine glioma
BrainChild Bio raised $116 million in Series A financing to advance CAR-T therapies into the central nervous system, funding a Phase 2 trial of its lead candidate for pediatric diffuse intrinsic pontine glioma while planning future adult indications.
Seattle Children’s Launches BrainChild Bio Startup to Develop CAR T-Cell Therapies for Pediatric Brain Cancer
Seattle Children’s has spun out BrainChild Bio, a biotech startup focused on developing CAR T-cell therapies for incurable pediatric brain cancers like diffuse intrinsic pontine glioma. Led by Dr. Michael Jensen, the company will operate from the Building Cure innovation hub in downtown Seattle.
Affini-T Therapeutics launched by Fred Hutch scientists including Juno co-founder Philip Greenberg to develop engineered TCR cancer therapies
Affini-T Therapeutics, founded by Fred Hutch scientists including Philip Greenberg (a Juno co-founder), Aude Chapuis and Thomas Schmitt, launched to develop T cell receptor (TCR) cancer immunotherapies that add engineered CD8 co-receptors and other gene edits. The Boston-headquartered company, led by CEO Jak Knowles, was unveiled at the J.P. Morgan Health Care Conference and will operate a research lab in Seattle.
Umoja Biopharma raises $210M Series B to advance in‑vivo T‑cell immunotherapies after $53M Series A seven months earlier
Umoja Biopharma, a Seattle-based immunotherapy startup, raised $210 million in a Series B just seven months after a $53 million Series A to advance in‑vivo T‑cell cancer therapies and tumor‑tagging technology into clinical trials for solid and hematological tumors.
Umoja Biopharma raises $53M Series A to develop in vivo CAR T-cell immunotherapies for adult and pediatric tumors
Seattle-based Umoja Biopharma raised $53 million in a Series A to advance its preclinical in vivo CAR T-cell immunotherapy platform for blood and organ tumors in adult and pediatric patients, aiming to generate cancer-fighting cells inside the body. The company was founded last year by CEO Andy Scharenberg and collaborators from Seattle Children’s Research Institute and Purdue University, with MPM Capital and Qiming Venture Partners USA leading the round.
Organizations
-
BrainChild Bio Founder and Chief Scientific Officer · current
